{"schema_version":"secwatch.filing_event.v1","accession":"0001022079-22-000136","form_type":"8-K","ticker":"DGX","cik":"0001022079","company_name":"QUEST DIAGNOSTICS INC","filed_at":"2022-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.262702+00:00","generated_at":"2026-06-23T02:09:10.035003+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Quest Diagnostics reports Q3 EPS $2.17, adjusted $2.36; raises 2022 guidance on base business growth of 5.1%","bullets":["Q3 2022 net revenues $2.49B, down 10.4% YoY; base business revenues $2.17B, up 5.1% YoY; COVID-19 testing $316M, down 55.4%.","Reported diluted EPS $2.17 (down 46.0%); adjusted diluted EPS $2.36 (down 40.4%).","Full-year 2022 guidance raised: net revenues $9.72B-$9.86B; adjusted EPS $9.75-$9.95 (prior $9.55-$9.95).","CEO transition: Jim Davis becomes CEO and President on Nov 1; Steve Rusckowski becomes Executive Chairman through March 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001022079-22-000136","json":"https://secwatch.observer/filing/0001022079-22-000136.json","markdown":"https://secwatch.observer/filing/0001022079-22-000136.md","text":"https://secwatch.observer/filing/0001022079-22-000136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022079/000102207922000136/0001022079-22-000136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022079/000102207922000136/dgx-20221020.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T02:09:10.035003+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}